VisEn debuts molecular agent, FMT systems

Sep 23, 2009

Optical imaging developer VisEn Medical has launched its ReninSense680 Fluorescent Activatable Sensor Technology (FAST) imaging agent, as well as two new additions to its fluorescence molecular tomography portfolio.

ReninSense680 FAST is designed to measure and monitor a hypertension and renal disease biomarker in vivo, according to the Bedford, MA-based vendor.

In other VisEn news, the company has introduced its FMT 1500 and FMT 2500 LX fluorescence molecular tomography systems. Designed for pharmaceutical companies and small to mid-sized research laboratories, FMT 1500 provides quantitative tomography in two fluorescence imaging channels, VisEn said.

FMT 2500 LX is a an advanced version of the company's FMT 2500 system, offering four imaging channels, a series of multimodality adaptors for integrated multimodality imaging, the company's TrueQuant image analysis suite, and a new reconstruction module for faster imaging times and expanded whole-body imaging applications, according to the firm.

VisEn expands product line, April 21, 2009

VisEn adds to management team, January 8, 2009

VisEn debuts IntegriSense, August 19, 2008

VisEn nets $3.5M in financing, July 22, 2008

$ChatGPT powered by GPT-4 and using DALL-E−3 was asked to generate an image for teaching purposes that demonstrated: a nuclear medicine bone scan with skeletal metastases (top left); coronary artery disease (top right); an F-18 FDG-PET scan of the brain with Alzheimer's disease (bottom left); and an x-ray showing a fracture (bottom right). These are misleading for educational purposes and for patients who may be searching for information. Image and caption courtesy of Radiography.$